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Abstract 
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Lysine deacetylases inhibitors (KDACIs) are used in basic research, and many are being investigated 
in clinical trials for treatment of cancer and other diseases. However, their specificities in cells are 
incompletely characterized. Here we used quantitative mass spectrometry to obtain acetylation 
signatures for 19 different KDACIs, covering all 18 human lysine deacetylases. Most KDACIs 
increased acetylation of a small, specific subset of the acetylome, including sites on histones and 
other chromatin-associated proteins. Inhibitor treatment combined with genetic deletion showed that 
the effects of the pan-sirtuin inhibitor nicotinamide are primarily mediated by SIRT1 inhibition. 
Furthermore, we confirmed that the effects of tubacin and bufexamac on cytoplasmic proteins result 
from inhibition of HDAC6. Bufexamac also triggered an HDAC6-independent hypoxia-like response 
by stabilizing HIF1-α, providing a possible mechanistic explanation of its adverse, pro-inflammatory 
effects. Our results offer a systems view of KDACI specificities, providing a framework for studying 
function of acetylation and deacetylases. 
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Intro 
Lysine acetylation is a reversible posttranslational modification that is controlled by the opposing 
activities of lysine acetyltransferases and deacetylases. The human genome encodes 18 different 
lysine deactetylases (KDACs), which play  important regulatory roles in several biological processes, 
including gene transcription
1
, silencing
2
, cytoskeletal reorganization and cell migration
3
 and DNA 
damage repair
4
. Depending on their sequence homology with yeast deacetylases as well as their 
domain organization and subcellular localization, KDACs are classified into four different classes 
(Fig. 1a). The importance of KDACs in mammalian physiology is highlighted by essential roles of 
many deacetylases in embryonic viability or postnatal development in mouse models
5-7
.  
Dysregulation of acetylation has been implicated in various human diseases, and thus KDACs are 
attractive therapeutic targets
8,9
 for diseases such as viral infections
10
, inflammation
11
, 
neurodegenerative diseases
12
, metabolic disorders
13
, and cancer
9
. In the past decade, >400 clinical 
trials have been initiated with different KDACIs, leading to the approval of vorinostat 
(suberoylanilide hydroxamic acid, SAHA) and romidepsin (FK228) for the treatment of cutaneous T-
cell lymphoma
14
. The therapeutic potential of KDACIs has encouraged the development of KDACIs 
with selectivity for different deacetylases, and currently more than a dozen different inhibitors are 
being tested in clinical trials
14-17
. 
The specificities of KDACIs have been extensively determined at the level of the enzyme that they 
target, often using in-vitro deacetylation assays with recombinant deacetylases
18
 or chemical 
proteomics-based approaches
19,20
. However, these methods do not reveal KDACI specificity in cells 
at the level of individual acetylation sites, which is critical for understanding their distinct modes of 
action and to stimulate scientific investigation and elucidate new therapeutic opportunities. 
Here we applied quantitative mass spectrometry (MS) to evaluate the specificities of 19 structurally-
divergent KDACIs at the level of acetylation sites affected in human cells. We quantified acetylation 
at more than 8,000 sites in inhibitor-treated HeLa cells and used genetic KDAC knockout cells to 
confirm the predicted specificities of several prominent KDACIs.  
 
Results 
Strategy for KDACI-regulated acetylome analysis 
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We selected 19 KDACIs that are widely used as research tools or drugs, and cover the entire 
selectivity range for human deacetylases, albeit with varying specificity profiles, as determined in 
previous studies using in-vitro deacetylation assays
18-20
 (Fig. 1a). In addition, we included a highly 
selective KDAC1 and 2 inhibitor, JQ12, which is an emerging chemical tool for studying isoform-
selective inhibition of class I KDACs (Supplemental note 1 and Supplemental Fig. 1a-c). 
To evaluate the selectivity of KDACIs for acetylation sites in cells,  we used a stable isotope labeling 
by amino acids in cell culture (SILAC)-based quantitative mass spectrometry (MS) approach
21
. 
Human cervical cancer (HeLa) cells were metabolically labeled with different stable isotopic forms 
of lysine and arginine (Lys
0
 and Arg
0, “light” SILAC; or Lys8 and Arg10, “heavy” SILAC). The 
“heavy” labeled cells were treated for 16 hours with the respective KDACIs, and their effects on 
acetylation levels were determined by comparison  with “light” labeled control cells that were mock-
treated with solvent (DMSO or H2O) (inhibitor concentrations are provided in Supplemental Table 
1). Acetylated peptides were enriched using anti-acetyllysine antibodies and analyzed by high 
resolution mass spectrometry
22
 (Fig. 1b).  
 
An overview of the KDACI acetylation screen 
For each of the KDACIs, site-specific acetylation changes were quantified in two independent 
biological replicates, which had an average Pearson correlation coefficient of 0.71 (Supplemental 
Fig. 2), supporting the overall quantitative reliability of the approach. Altogether, the dataset 
contains >8,100 quantified acetylation sites in HeLa cells (Supplemental Table 2), covering ~80 % of 
previous identified sites
23
 (Supplemental Fig. 3), which were localized to the indicated lysines with 
greater than 90 % confidence (average site localization probability of 0.99). A majority (~85 %) of 
the acetylation sites was quantified in more than one KDACI-treated sample, and nearly 60 % of the 
sites were quantified in response to five or more KDACIs (Supplemental Table 2). 
We quantified an average of >3,200 acetylation sites for each of the analyzed KDACIs (Fig. 1c), 
enabling us to assess in cells the inhibitory scope and acetylation pattern for each of the tested 
compounds. For further analyses, we set a threshold of a greater than two-fold increase or decrease in 
acetylation for regulated acetylation sites. Notably, most inhibitors increased acetylation of only a 
small fraction of the quantified sites (on average 6.2 %) above this threshold (Fig. 1c), demonstrating 
that a majority of KDACIs have a limited, though specific, inhibitory scope at the acetylation site 
level. The activity of KDACs diminishes protein acetylation levels; accordingly, for all investigated 
Field Code Changed
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inhibitors except sirtinol, the fraction of upregulated acetylation sites in KDACI-treated cells was 
greater than the fraction of downregulated sites (Fig. 1c). 
 
Specificity of KDACIs for acetylation sites 
To understand the specificity patterns of KDACIs in cells, we used average linkage clustering to 
group KDACIs based on their effects on the hyperacetylation of sites in cells. Many of the classical 
histone deacetylase inhibitors, such as LBH589, PXD101, SAHA, TSA, grouped together, and this 
group was closely related to the group of KDACIs targeting class I deacetylases including apicidin, 
MS275, CI.994, MGCD0103, and valproic acid (VPA) (Fig. 2a). The acetylation specificity profiles 
of many of these inhibitors in cells (i.e., apicidin, MS275, CI.994, MGCD0103) are consistent with 
their described deacetylase inhibitory profiles in cell-free systems. However, the inhibitory profiles 
of several KDACIs, such as tenovin-6, sirtinol and nicotinomide (NAM), were distinct from each 
other and from the remaining KDACIs.  
We examined the subcellular distribution of proteins with KDACI-upregulated acetylation sites by 
association of acetylated proteins with the Gene Ontology (GO) terms “Nuclear”, “Cytoplasm”, and 
“Mitochondrial” (Fig. 2b). A majority of inhibitors caused increased acetylation of nuclear proteins 
and for eight of the inhibitors, more than 60 % of upregulated acetylation sites were present on 
nuclear proteins (compared to 30 % of all sites). Acetylation of N-terminal lysines in histones has 
numerous regulatory roles
24,25
. Several inhibitors of Class I and IIa KDACs showed similar 
regulatory profiles for histones and strongly increased acetylation of N-terminal lysines, whereas 
other KDACIs such as PCI34051, sirtinol and tenovin-6 did not cause extensive acetylation of the N-
terminal histone tails (Fig. 2c). A large number of acetylation sites was also quantified on the middle 
and C-terminal parts of histones; however, most of these sites were not similarly upregulated by the 
KDACIs, indicating that histone deacetylases function in a site-selective manner and differentially 
affect distinct sites on the same proteins. 
Tenovin-6, NAM, and tubacin were among the most promiscuous inhibitors, each increasing 
acetylation at more than ten percent of all quantified sites (Fig. 1c). However, the acetylation profiles 
of these inhibitors were relatively distant from each other, and from that of most other inhibitors 
(Fig. 2a). Many acetylation sites were commonly quantified in cells treated with broad-range 
inhibitors such as tenovin-6, NAM, PCI24781, and tubacin; however, few sites were commonly 
regulated by these inhibitors (Fig. 2d). Thus, each of these inhibitors affects a large, but distinct, 
Field Code Changed
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subset of acetylation sites. Among these four KDACIs, only tubacin and PCI24781-upregulated sites 
showed a substantial overlap, consistent with both compounds targeting HDAC6
26,27
.  
Based on the fraction of upregulated sites, the HDAC8-specific inhibitor PCI34051
28
 was the most 
selective KDAC inhibitor in our screen (Fig. 1c). We identified SMC3 acetylation as a key target of 
this inhibitor (Supplemental Table 2, Supplemental Fig. 4a, b). Acetylation of lysines K105/K106 of 
SMC3 is important for the establishment of chromosome cohesion
29-31
. These results confirm a 
recent study that identified HDAC8 as a SMC3 deacetylase
32
 and indicate that HDAC8, at least in 
cultured human cells, functions as a highly selective deacetylase targeting only a few proteins. 
Considering the broad effects of tubacin, bufexamac, tenovin-6, and NAM, and their distinct 
acetylation profiles, we decided to further analyze the mechanisms and properties of the acetylation 
sites and proteins that were affected by these inhibitors.  
NAM increases acetylation of nuclear sites 
Sirtuin deacetylases require the cofactor NAD
+
 for deacetylase activity and generate nicotinamide 
(NAM) from NAD
+
 during the deacetylation reaction. NAM, which noncompetitively inhibits 
sirtuins without affecting their binding of NAD
+33
, has been widely used as a pan-sirtuin inhibitor. In 
our dataset, NAM was among the inhibitors that affected the largest number of sites and increased 
acetylation more than two-fold at 12% of sites, and more than 1.5-fold at 20 % of sites (Fig. 1c), 
suggesting a broad substrate range for sirtuin deacetylases. NAM-sensitive acetylation sites were 
predominantly present on nuclear proteins that are involved in diverse biological processes in this 
compartment (Fig. 2b, 3a).  Acetylation of most mitochondrial proteins was not specifically 
increased even after long-term (72h) treatment with NAM (Supplemental Fig. 5a-c, Supplemental 
Table 3), despite sirtuins being the only known deacetylases in this organelle (Fig. 2b, Supplemental 
Table 4). These unexpected results were independently confirmed in human acute myelocytic 
leukemia cells (MV4-11) (Fig. 3b, Supplemental Table 5).  
Among the NAM-upregulated acetylation sites, many were present on known substrates of SIRT1 
such as p53, BAZ2a, NPM1, MOF, WRN, Ku70 and Ku80 (Supplemental Tables 4, 5). In addition, 
many proteins with NAM-upregulated acetylation sites were interconnected in functional networks, 
and were enriched in Gene Ontology (GO) terms such as transcription, splicing, and DNA damage 
(Supplemental Fig. 6a).  
In order to identify the cellular deacetylases that are targets of NAM, we compared NAM-regulated 
acetylation in mouse embryonic fibroblasts (MEFs) to acetylation changes caused by deletion of 
Field Code Changed
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Sirt1, Sirt2, or Sirt6 (Supplemental Fig. 6b-c, Supplemental Tables 6-9), which are known to 
deacetylate proteins in non-mitochondrial compartments. Similar to NAM treatment, and in 
agreement with a previous study
34
, acetylation was increased at several hundred sites in Sirt1
-/-
 cells 
(Supplemental Table 6). The SIRT1- and NAM-regulated acetylomes showed a strong correlation 
(R = 0.63) (Fig. 3c), and similar GO terms were enriched in the NAM- and SIRT1-regulated 
acetylomes (Fig. 3d), suggesting that SIRT1 is the major target of NAM in cells. This is also 
supported by a good correlation of NAM- and the SIRT1 inhibitor EX-527-regulated acetylomes 
(R = 0.68) (Supplemental Fig. 7, Supplemental Table 10).  In contrast, a smaller fraction of the 
acetylome changed in Sirt2
-/-
 and Sirt6
-/-
 cells compared to Sirt1
-/-
 cells, and these changes correlated 
weakly with NAM-induced changes (R = 0.1) (Supplemental Fig. 6d, 8). SIRT2-regulated 
acetylation also showed a modest correlation with the SIRT2 inhibitors sirtinol and AGK2 (R = 0.11 
for sirtinol vs Sirt2
-/-
; R = 0.35 for AGK2 vs Sirt2
-/-
) (Supplemental Fig. 8, Supplemental Tables 8, 
9), indicating that these inhibitors weakly inhibited SIRT2 in MEFs at the concentrations used in our 
study.  
 
Tenovin-6 increases mitochondrial acetylation 
We and others have previously identified a large number of acetylation sites on mitochondrial 
proteins in human cells
22,35,36
; however, no KDACI has been demonstrated to selectively increase 
acetylation of mitochondrial proteins. In our screen, we identified tenovin-6 as a specific regulator of 
mitochondrial acetylation (Fig. 2b and Supplemental Fig. 9a). In total, 405 acetylation sites showed 
elevated acetylation upon tenovin-6 treatment (Supplemental Table 2), and a large majority of these 
sites (more than 90 %) was present on proteins annotated as mitochondrial (Supplemental Fig. 9b); 
corresponding to more than 50 % of all identified mitochondrial acetylation sites in tenovin-6 treated 
cells. Several mitochondria-related Gene Ontology (GO) terms, such as ATP synthetase complex, 
mitochondrial matrix, and mitochondrial lumen, showed significant enrichment among proteins with 
tenovin-6-upregulated acetylation sites (Supplemental Fig. 9b). Also, enzymes that participate in 
metabolic pathways, such as the TCA cycle and fatty acid elongation, were significantly enriched 
within the group of differentially acetylated proteins (Supplemental Fig. 9c,d). These data 
demonstrate that tenovin-6, an anti-cancer compound, specifically increases acetylation of 
mitochondrial proteins.  
 
Tubacin and bufexamac inhibit HDAC6  
Field Code Changed
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Tubacin and bufexamac were among the few inhibitors that affected a broad substrate range with 
similar acetylation changes (Fig. 4a) and increased acetylation of the well-known HDAC6 substrate 
cortactin
37
 (Supplemental Tables 2, 11). Tubacin and bufexamac have been reported to be selective 
for HDAC6
19,27
, and the broad effects on the cellular acetylome we observed prompted us to 
investigate whether these changes are mediated via HDAC6 or through independent mechanisms. 
We found that deletion of Hdac6 also affected a large number of acetylation sites in MEF cells, and 
HDAC6-regulated acetylation changes correlated with those caused by tubacin and bufexamac 
treatment (R = 0.54 for bufexamac vs Hdac6
-/-
; R = 0.53 for Tubacin vs Hdac6
-/-
) (Fig. 4b, c; 
Supplemental Table 12). Furthermore, similar GO terms were enriched among proteins with 
increased acetylation in response to inhibitor treatment or deletion of Hdac6 (Fig. 4d). These data 
showed that a large fraction of bufexamac- and tubacin-regulated acetylation is likely to be caused 
by inhibition of their endogenous target deacetylase HDAC6. 
Bufexamac activates the HIF1- pathway 
Until recently, bufexamac was used as a non-steroidal anti-inflammatory drug (NSAID) for the 
treatment of inflammatory dermatoses, but due to growing evidence that it can provoke contact 
dermatitis, its clinical use was revoked in Europe in 2010
38
. The mechanisms by which bufexamac 
causes inflammation remain unknown.  
A majority of bufexamac-based ointments  thought to be anti-inflammatory contained very high 
concentrations of this compound (~5 %, corresponding to 224 mM), whereas it is known that 
bufexamab efficiently increases acetylation of the HDAC6 target tubulin at 10,000-fold lower 
concentrations (less than 10 M)19 (see also Fig. 5g). To understand the possible mechanistic basis of 
its pro-inflammatory effects, we analyzed changes in lysine acetylation and protein expression in 
HeLa cells treated with two different concentrations of bufexamac (50 µM [0.001 %] and 1 mM 
[0.022 %]) (Supplemental Fig. 10a). The high dose concentration used here is similar to the lowest 
doses of bufexamac that are sufficient to cause inflammatory reactions in patients
39
. High-dose 
bufexamac substantially increased abundance of an acetylated peptide from hypoxia-inducible factor 
1 alpha (HIF1- (Supplemental Fig. 10b, Supplemental Table 2). HIF1-α is a transcription factor 
that plays essential roles in the cellular responses to hypoxia, and acetylation can stabilize HIF1- 
protein by preventing its proteasomal degradation
40
. Indeed, HIF1- was strongly induced by 
bufexamac and the increase in HIF1-levels was comparable to commonly used hypoxia mimetics 
such as ciclopirox olamine (CPX) and deferoxamine (DFX) (Fig. 5a). In contrast to bufexamac, two 
other well-knows NSAIDs, aspirin and ibuprofen, failed to increase HIF1-protein levels indicating 
Field Code Changed
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that this effectis specific to bufexamac (Fig. 5b). HIF1-was rapidly stabilized (Fig. 5c), and 
accumulated in the nucleus of bufexamac treated cells (Fig. 5d).  
Bufexamac readily increased the transcriptional activity of HIF1-α in a luciferase reporter assay (Fig. 
5e), as well as increased the expression of its endogenous target gene vascular endothelial growth 
factor A (VegfA) (Fig. 5f). Furthermore, we analyzed changes in protein expression in bufexamac-
treated cells by quantifying over 5,800 proteins (Supplemental Table 13). Among 23 proteins that 
were reproducibly upregulated by high-dose bufexamac in all three experiments, over 70 % were 
previously known to be upregulated by hypoxia (Supplemental Fig. 10c, Supplemental Table 13). In 
contrast, none of those proteins were consistently upregulated in the low-dose bufexamac-treated 
cells. These results confirmed the induction of hypoxia-like responses in bufexamac-treated cells. 
Notably, stabilization of HIF1- occurred only at relatively high doses (>200 M) of bufexamac, 
whereas increased acetylation of tubulin was already detectable at substantially lower doses (>5 M) 
(Fig. 5g). These results suggested that bufexamac-induced hypoxia responses may occur 
independently of its KDAC inhibitory functions. Bufexamac is a hydroxamic acid compound, and 
many compounds of this class function as metal chelators. Because iron chelators are commonly 
used as hypoxia mimetics, we surmised that bufexamac may induce hypoxia-like responses by 
chelating cellular iron. Indeed, supplementation of iron during bufexamac treatment abolished 
bufexamac-induced HIF1- protein induction in a dose-dependent manner (Fig. 5h) as well as its 
transcriptional activity (Fig. 5i). Treatment of iron-dependent HL-60 (Human promyelocytic 
leukemia cells) cells with bufexamac caused cell death, and this effect was completely reversed by 
iron substitution (Supplemental Fig. 11). A direct interaction between bufexamac and iron was 
further shown by colorimetric iron chelation assay using UV/VIS spectroscopy (Supplemental Fig. 
12a, b). Taken together, these results show that at lower doses bufexamac specifically inhibits 
HDAC6, whereas at higher concentrations it also chelates cellular iron, thereby activating the HIF1-
 pathway by mimicking hypoxia (Supplemental Fig. 13). 
 
Discussion 
A large number of small molecule KDAC inhibitors has been identified that show distinct selectivity 
for different deacetylases
8,9,16
. In addition to their clinical use, KDACIs are commonly used in basic 
research to study function of acetylation and deacetylation. Specificity profiles generated in cell-free 
systems are frequently used as a reference for selecting appropriate KDACIs.  Knowing KDACIs 
Field Code Changed
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targets is important for interpreting the effects of inhibitors both in research and clinical settings. We 
provide a detailed comparison of KDACI specificities at the level of affected sites, shedding insights 
into their specificities for acetylation sites in cells (Supplemental Figure 14; Supplemental note 2). 
For several KDACIs, the number of acetylation sites affected is not proportional to the number of 
KDACs they were found to inhibit in cell-free assays, which is consistent with recent studies 
demonstrating  unexpected selectivities of KDACIs in-vitro
18,19
. Our results complement data from 
cell-free systems and emphasize the importance of evaluating KDACI effects at the acetylation site 
level to better understand and refine the specificities of KDACIs.  
Analysis of acetylation in several genetically defined cells showed that broad-range inhibitors NAM, 
tubacin and bufexamac increase acetylation through inhibition of SIRT1 and HDAC6. Most other 
inhibitors of Zn
2+
-dependent deacetylases targeted multiple deacetylases (Fig. 1a) and commonly 
inhibit class I deacetylases. HDACs 1-3 are essential for cell viability, so we could not confirm their 
acetylation targets in knockout cells. However, several data indicate that these KDACIs regulate 
acetylation by specifically inhibiting class I HDACs: (i) acetylation was regulated in a site-specific 
manner, (ii) KDACIs increased acetylation of nuclear proteins, where their target deacetylases are 
present, and (iii) they increased acetylation of sites present on the N-terminal tails of histones, many 
of which are known to be regulated by class I deacetylases. Contrary to their reported broad 
inhibitory effects on deacetylases in cell-free systems
18,41
, most of these KDACIs increased 
acetylation of small but specific, subsets of the acetylome. The scope of these inhibitors was more 
limited than tubacin and bufexamac which inhibit only HDAC6 (and perhaps HDAC10), indicating 
that at concentrations applied here these inhibitors more potently inhibit class I deacetylases, but less 
potently inhibit HDAC6. The acetylation signatures of sirtuin inhibitors tenovin-6, NAM and sirtinol 
are not fully consistent with their predicted inhibitory profiles, indicating that disparitites between 
cell-free and cell-based acetylation profiles are not uncommon.  
NAM and sirtinol were identified as inhibitors of yeast Sir2
33
, and are used as sirtuin class 
deacetylase inhibitors. In this study, NAM-upregulated 12 % of acetylation sites, whereas sirtinol 
affected less than 2 % of sites, indicating that the scope of these inhibitors is vastly different. In 
contrast to several canonical KDACIs that inhibit Zn
2+
-dependent deacetylases, NAM increased 
acetylation of many non-histone proteins in the nucleus without causing widespread increase in 
histone acetylation levels. However, NAM increased acetylation on several histone-modifying 
enzymes such as acetyltransferases and methyltransferases, and other chromatin-associated proteins. 
The low overlap (~10 %) between sites upregulated by NAM and all non-sirtuin targeting KDACIs 
suggests a minimal redundancy between sirtuins and Zn
2+
-dependent histone deacetylases. We found 
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that most of the NAM-induced acetylation changes were mediated through inhibition of SIRT1, 
highlighting the broad target range of SIRT1 and suggesting that the physiological effects of NAM 
may be primarily mediated by inhibiting SIRT1 function.  
Mitochondria exclusively contain NAD
+
-dependent deacetylases, and thus our results showing only a 
modest increase in mitochondrial acetylation by NAM are unexpected. The possible reasons for this 
remain unclear, but it could be that mitochondrial sirtuins are less sensitive to NAM, that NAM is 
excluded from mitochondria, or that NAM is rapidly metabolized to NAD
+
 by nicotinamide 
phosphoribosyltransferase (NAMPT)
42
. Metabolic conversion of NAM to NAD
+ 
may result in lower 
effective concentrations of NAM, and subsequent import of NAD
+
 into mitochondria may counteract 
its effect by activating sirtuins in this compartment. Tenovin-6 inhibits SIRT1 and SIRT2 in cell-free 
systems, whereas it weakly inhibits SIRT3
43
; however, in cells, it increased acetylation of 
mitochondrial proteins, which suggests that it may increase acetylation by a yet unknown 
mechanism. With the emerging role of mitochondrial acetylation in regulating diverse metabolic 
pathways
44,45
 and its relevance to the stress response
46,47
, the identification of tenovin-6 as a potent 
inducer of mitochondrial acetylation may further facilitate studying the functional relevance of 
acetylation in this context.  
Bufexamac has long been used as non-steroidal anti-inflammatory drug (NSAID) for the treatment of 
dermatoses. It was revoked in 2010 due to its adverse reactions that caused contact dermatitis
39
, but 
the mechanisms of bufexamac-mediated inflammation remained unknown. We showed that at higher 
concentrations (>200 M) it chelates cellular iron, potently stabilizes HIF1-, and induces 
downstream hypoxia-like responses (Supplemental Fig. 13). The concentrations of bufexamac 
present in most anti-inflammatory would be more than adequate to cause local hypoxia-like 
responses at the applied regions. Furthermore, the drug was applied at already inflamed regions, 
making it plausible that even much lower doses than that present in the prescribed ointments would 
have been sufficient to induce hypoxic responses. The connection between hypoxia and 
inflammation is well described
48
. Thus, our data provide new insights into the possible mechanistic 
basis of the bufexamac-inflammation paradox and illustrate the usefulness of unbiased proteomic 
analyses in discovering cellular mechanisms of drugs. 
Although the global acetylome analyses applied here provide a powerful approach for obtaining an 
unbiased (non-hypothesis driven) picture of cellular targets of KDACIs, caution should be taken in 
interpreting the biological functions of KDACI-regulated acetylation sites. First, while we have 
applied a 2-fold change as a cut-off to classify KDACI-regulated sites, it is possible that less robust 
12 
 
changes (i.e. 50 % increases in acetylation) could have important biological consequences. Second, 
in this work we compared changes in acetylation using a single inhibitor dose and time point, though 
it is plausible that the effects of KDACIs are dose- and time-dependent, and that by varying doses 
and treatment times one may identify additional substrates. Third, our analyses cannot distinguish 
between direct and indirect targets of deacetylases inhibited by KDACIs. Thus, for functional 
investigations of specific acetylation sites it is important to independently verify their regulation by 
KDACIs using varying doses and time points. Nevertheless, our results offer a snapshot of the 
KDACI substrate spectrum at the most commonly used doses, providing a road-map for further 
investigations. 
In summary, our results portray a global picture of acetylation sites regulated by KDACIs and their 
several downstream deacetylases, and provide a detailed comparative view of their regulatory 
scope.These results exemplify the usefulness of quantitative MS screens in revealing endogenous 
acetylation profiles for known KDACIs in cells and in identifying selective KDACIs for sites of 
interest. In addition to elucidating broad outlines of acetylation inhibition, we anticipate that this 
resource dataset will be useful in investigating the functional roles of deacetylases and their target 
sites, in understanding the molecular basis of drugs targeting deacetylases, in evaluating specificity 
of novel KDACIs, and in developing new therapies. 
 
Footnotes 
The supplementary information contains part of the data reported in this manuscript and a detailed 
description of all materials and methods used to obtain the data. 
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Online Methods 
Materials 
KDACIs were purchased either from Sigma-Aldrich, Selleckchem or Chemie-Tek. All other 
standard chemicals were obtained from Sigma-Aldrich and Merck KGaA. Cell culture media and 
reagents were from Invitrogen. SILAC amino acids were purchased from Cambridge Isotope 
Laboratories. Agarose-conjugated anti-acetyllysine antibodies were purchased from Immunechem 
Inc. (Catalog no.: ICP0388). Antibodies for immuno-blotting were purchased from Abcam (H3Ac-
K122, ab33309), Millipore (H4Ac-K16, 07-329), Cell Signalling (Ac-tubulin, 5335P; Ac-Lysine, 
9441; SIRT1, 2028; c-myc, 2276), Sigma Aldrich (vinculin, V9264; tubulin, T5326), Santa Cruz 
(SMC3, sc-376352; HDAC8, sc-374180), and Epitomics (HIF1-α, 2015-1). Anti-mHDAC6 antibody 
was generated by P. Matthias lab; purified recombinant protein antigen corresponding to the C-
terminal ZnF-domain of mHDAC6 was injected into rabbits (Pocono rabbit farm & laboratory; USA) 
and serum containing mHDAC6 antibody was used for further antibody purification. 
HDAC biochemical assay for JQ12 
JQ12 was tested against HDAC1-9 and the activity was determined with an optimized homogenous 
assay performed in a 384-well plate. Compound was incubated with HDAC enzyme for 3 h. 
Reactions were performed in assay buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 0.05 % 
BSA and pH 7.4. Additional 200 μM TCEP was added for HDAC6) and followed by fluorogenic 
release of 7-amino-4-methylcoumarin from substrate upon deacetylase and trypsin enzymatic 
activity. Fluorescence measurements were obtained every five minutes using a multilabel plate 
reader and plate-stacker (Envision; Perkin-Elmer). Each plate was analyzed by plate repeat, and the 
first derivative within the linear range was imported into analytical software (Spotfire DecisionSite). 
Replicate experimental data from incubations with inhibitor were normalized to DMSO controls 
([DMSO] < 0.5 %). IC50 was determined by logistic regression with unconstrained maximum and 
minimum values (Supplemental Figures 1B and 1C). The recombinant, full-length HDAC protein 
(BPS Biosciences) was incubated with fluorophore conjugates substrate, MAZ1600 and MAZ1675 at 
Km = [substrate].  
Cell culture, SILAC labeling, preparation of cell lysates and protein digestion 
Double SILAC Experiments: 
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HeLa (ATCC: CCL-2) and MV4-11 (ATCC: CRL-9591) cells, were grown in DMEM and RPMI, 
respectively, supplemented with 10 % FBS, 2 mM L-glutamine, and 1 % penicillin/streptomycin. For 
SILAC labeling, cells were cultured in the appropriate medium containing either L-arginine and L-
lysine (light label) or L-arginine-
13
C6-
15
N4 and L-lysine-
13
C6-
15
N2 (heavy label). All cells were 
cultured at 37°C in a humidified incubator at 5 % CO2. At a confluency of ~90 %, heavy-labeled 
cells were treated for 16 h with the respective HDAC inhibitor (for concentrations used in this study, 
please refer to Supplemental Table 1), whereas light labeled cells were mock-treated with DMSO 
and H2O, respectively. Each experiment was performed at least in biological duplicates. Cells were 
washed twice with PBS and lysed in modified RIPA buffer (50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mM EDTA, 1 % NP-40, and 0.1 % sodium deoxycholate, supplemented with complete 
protease inhibitor mix (Roche). Lysates were mixed with 1/10 volume of 5 M NaCl to release 
chromatin-bound proteins and incubated for 15 min on ice. Subsequently, lysates were homogenized 
by sonication (6 x 10 sec, 15 W), cleared by centrifugation (20.000 x g, 15 min, 4°C), and proteins 
were precipitated overnight at -20°C by the addition of 4 volumes of ice-cold acetone. Precipitates 
were redissolved in 8 M urea (6 M urea, 2 M thiourea) and protein concentration was determined by 
Quick-start Bradford assay (Bio-Rad). Corresponding SILAC labeled proteins (heavy and light 
labeled) were mixed in a 1:1 ratio, reduced with 1 mM DTT (45 min, RT), and alkylated by 5.5 mM 
chloracetamide (45 min, RT). Following, 20 mg proteins were digested by endoproteinase Lys-C 
(1:100 w/w; Wako) and, after 4-fold dilution with HEPES buffer (50 mM; pH 7.5), by modified 
sequencing grade trypsin (1:100 w/w; Sigma-Aldrich). Digestion was stopped by the addition of 
trifluoroacetic acid (TFA) to a final concentration of 1%.  
Triple SILAC Experiments: 
Mouse embryonic fibroblast (MEF) cells (wildtype (WT), Hdac6
-/- 50
, Sirt1
-/- 51
, Sirt2
-/- 52
, Sirt6
-/- 53
) 
were grown in DMEM as described above. For SILAC labeling, WT cells were cultured in DMEM 
containing either L-arginine and L-lysine (light label), or in medium supplemented with 
L-arginine-
13
C6 and L-lysine-
 2
H4 (medium label), whereas the corresponding knockout (KO) cells 
were heavy labeled using DMEM containing L-arginine-
 13
C6-
15
N4 and L-lysine-
 13
C6-
15
N2. At a 
confluency of ~90 %, medium-labeled WT cells were treated for 16 h with the respective HDACIs, 
whereas light labeled WT, and heavy labeled KO cells were mock-treated with DMSO and H2O, 
respectively. All experiments were performed in at least two biological replicates. Cells were 
harvested as described above, lysed, and proteins were mixed in a 1:1:1 ratio prior to reduction with 
DTT, alkylation with chloracetamide and trypsin digestion, as described above. 
Field Code Changed
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Purification of peptides and enrichment of acetylated peptides 
Digested protein samples were cleared for precipitates by centrifugation (2,500 x g, 5 min) and 
loaded onto reversed-phase C18 Sep-Pak columns (Waters), pre-equilibrated with 5 ml acetonitrile 
and 2 x 5 ml 0.1 % TFA. Peptides were washed with 0.1 % TFA and H2O, eluted with 50 % 
acetonitrile (ACN) and mixed with 100 µl 10x IAP buffer (500 mM MOPS; pH 7.2, 100 mM Na-
phosphate, 500 mM NaCl). Subsequently, ACN was removed and volume of samples was adjusted 
to 1 ml by H2O. For proteome analysis, small aliquots of total peptides were fractionated using 
micro-SCX columns in a stage-tip format
54
. Peptide fractions were purified and concentrated with 
reversed-phase StageTips as described
54
. For acetylation enrichment, modified peptides were 
immunoenriched using anti-acetyllysine antibodies (40 µl / IP) as described previously
22
. Enriched 
peptides were fractionated and purified as described for proteome samples. Peptides were eluted with 
40 µl of buffer B (60 % ACN, 0.1 % TFA) and organic solvent was removed in a SpeedVac 
concentrator. The final sample volume was adjusted to 7 µl with buffer A* (0.5 % acetic acid, 0.2 % 
TFA). 
Mass spectrometric analysis 
Peptide fractions were analyzed by online nanoflow LC-MS/MS with a Proxeon easy nLC system 
(Thermo) connected to a Q Exactive mass spectrometer (Thermo) as described previously
55
. Briefly, 
peptide samples were loaded onto C18 reversed-phase chromatography columns (length 15 cm, inner 
diameter 75 µm) and eluted with a linear gradient of 6-40 % ACN/H2O containing 0.5 % acetic acid. 
Eluted peptides were ionized by electrospray-ionization and measured in the mass spectrometer. 
Typical mass spectrometric conditions were: spray voltage: 2.0 kV, no sheath and auxiliary gas flow, 
heated capillary temperature: 275°C. The Q Exactive under Xcalibur 2.2 with LTQ Orbitrap Tune 
Plus Developers Kit version 2.6.0.1042 software was operated in data dependent mode to 
automatically switch between MS and MS2 acquisitions as described previously
56
.  
Peptide identification and quantification 
All MS data were analyzed with MaxQuant (development version 1.2.7.1)
57
. All SILAC pairs were 
quantified and MS/MS spectra were searched against the human Uniprot FASTA database (released 
in February 2012) to identify corresponding proteins. The false-discovery rate (FDR) was fixed to a 
threshold of 1 % FDR at peptide and protein level and all peptide identifications were filtered for 
length and mass error. FDR was estimated using a target-decoy database search approach
58
 . 
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Cysteine carbamidomethylation was searched as a fixed modification, whereas methionine oxidation, 
N-acetyl protein, and acetylation of lysine were chosen as variable modifications.  
Immunofluorescence microscopy 
HeLa cells were treated without or with bufexamac (50 and 250 µM) for 4 h at 37°C. Subsequently, 
cells were fixed by 2 % paraformaldehyde (PFA) in PBS and permeabilized with 0.2 % Triton-X in 
PBS. After blocking with 5 % bovine serum albumin (BSA) in PBS, cells were incubated with 
primary antibody (anti-acetyl-tubulin and anti-HIF1-α) and subsequently with anti-rabbit secondary 
antibody coupled to Alexa Fluor 488 and 568 (Molecular Probes). Cells were mounted by using 
DAPI containing Vectashield mounting medium (Vector labs). Confocal images were acquired on a 
LSM-780 (Carl Zeiss Microimaging Inc.) mounted on Zeiss-Axiovert 100M equipped with Plan-
Neofluar 40 x/1.3 oil immersion objective. 
Luciferase assays 
HeLa cells were transfected with hypoxia responsive element (HRE)-Luciferase plasmid (Addgene; 
plasmid No. 26731;
59
) and treated as indicated. Activation of hypoxia response elements was 
determined by measuring luciferase activity using the Dual-Glo Luciferase Kit (Promega) according 
to the manufacturer´s protocol.  
QPCR  
HeLa cells were pretreated without or with bufexamac (50 and 250 µM) and Desferoxamine 
mesylate (200 µM), and subsequently RNA was isolated using the Qiagen RNeasy kit (Qiagen) 
according to manufacturer´s protocol. The same procedure was used to obtain RNA from wt and KO 
MEF cells. Total RNA was quantified using a nano-drop spectrophotometer (Thermo) and 
complementary DNA (cDNA) was synthesized using the QuantiTect Rev. Transcription kit 
(Qiagen). Reverse transcription reactions were diluted 1:5 with H2O and stored at -20°C. 
Quantitative PCR was performed using a Stratagene Mx3005P instrument. Experimental data was 
analyzed with MxPro software. Sample setup and QPCR reactions were performed as described
60
. 
For  each QPCR reaction run a  glyceraldehyde-3- phosphate dehydrogenase (Gapdh) standard curve 
was prepared by 1,000-fold serial dilution (10x at each point) and the PCR efficiency was 
determined. The PCR efficiency was then used to calculate the abundance of cDNA for the target 
gene relative to Gapdh.  The following primers (Hs, Homo sapiens; Mm, Mus musculus) were used 
for QPCR: HsGapdh, forward: 5’-CAGCGACACCCACTCCTCCA-3’ and reverse: 5’-
GCTGGTGGTCCAGGGGTCTT-3’; HsVegfA, forward: 5’-CGAGACTCCGGCGGAAGCAT-3’ 
18 
 
and reverse: 5’-CGGCCGCGGTGTGTCTACAG-3’; MmGapdh, forward: 5’-
TCCATGACAACTTTGGCATTG-3’ and reverse: 5’-CAGTCTTCTGGGTGGCAGTGA-3’; 
MmSirt2, forward: 5’-CGAAGGAGTGACACGCTACATG-3’ and reverse: 5’-
GGTGGTACTTCTCCAGGTTTGC-3’; MmSirt6, forward: 5’-
CAGTACGTCAGAGACACGGTTG-3’ and reverse: 5’- GTCCAGAATGGTGTCTCTCAGC-3’.  
Immuno-blotting 
For immuno-blotting, protein lysates were prepared in modified RIPA buffer and protein amounts 
measured by Bradford assay. Equal amounts of proteins were precipitated by ice-cold acetone and 
precipated proteins were recovered by centrifugation (20.000 x g, 2 min, 4°C). Proteins were 
redissolved in 4x sample buffer containing 100 mM DTT, and separated on NuPAGE Novex 4-12 % 
Bis-Tris gels (Invitrogen) and visualized by immuno-staining with the indicated antibodies.  
Immuno-precipitation of SMC3 
HeLa cells were treated with different concentrations of PCI34501, washed with PBS, lysed with IP-
wash buffer (5 mM MgCl2, 1 mM CaCl2, 1 mM EDTA, 0.1 % Triton X-100 in PBS; pH 7.4, 
supplemented with complete protease inhibitor mix (Roche)) containing 1 % Triton X-100 and 
clearified by centrifugation (20.000 x g, 15min, 4°C)). For detection of HDAC8-inhibitor dependent 
acetylation of SMC3, protein G magnetic Dynabeads (Dynal) were pre-loaded with anti-SMC3 
antibody for 2 h at 4°C. Control IPs were performed using an antibody against c-Myc epitope tag. 
After coating, beads were washed three times with ice-cold IP-wash buffer. Subsequently, beads 
were incubated for 2 h at 4°C with cell lysates. After washing three times with IP-wash buffer and 
three times with cold PBS proteins were eluted with 50 µl SDS sample buffer for 10 min at 65°C. 
Eluates were analyzed by SDS-PAGE and subsequent immuno-blotting using a pan-anti-acetyllysine 
antibody.  
 
Determination of cell death 
Human promyelocytic leukemia (HL-60) cells (ATCC: CCL-240) were treated as indicated. 
Subsequently, cell viability was determined using propidium iodide (PI) staining solution (Cayman 
Chemical Company). Cells were stained according to the manufacturer´s protocol and PI 
fluorescence was measured in a plate reader.  
 
Iron binding assay 
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Bufexamac (5 mM in methanol) and desferoxamine mesylate (5 mM in methanol), were titrated in 2 
µl increments into 500 µl of a 100 µM methanolic FeCl3 solution and iron-complex formation was 
measured at a wavelength of 490 nm using a Varian Cary 50Bio UV-Vis Spectrophotometer. 
Absorption was plotted against chelator concentration and fitted to a Langmuir (1:1) isotherm 
[𝑦 = 𝑎 ∗
𝑥
𝐾𝐷+𝑥
] to derive the dissociation constant (KD). All binding assays were performed using 
methanol as solvent due to very low solubility of bufexamac in aqueous solutions, and thus, these KD 
values may differ from values in aqueous solutions. 
Data analysis 
Statistical analysis was performed using the R software environment (http:// http://www.r-
project.org/) and biochemical data was analyzed using Graphpad Prism (version 5). Gene ontology 
(GO) term enrichment was calculated using Fisher exact test. P-values were adjusted for multiple 
hypotheses testing using the false discovery rate (FDR)-method. Protein interaction network analysis 
was performed using interaction data from the STRING database (version 9)
61
. Only interactions 
with a STRING score above 0.7 are represented in the network, and visualized using Cytoscape
62
 
and ClueGO / GOlorize plug-ins
63,64
.  
Site-based clustering of inhibitors 
To define an acetylation site-based similarity of two inhibitors, we selected the sites that were 
identified for both KDACIs and showed increased acetylation (SILAC ratio >2) for at least one of 
the two inhibitors. We next log-transformed the ratios and defined the similarity as the Pearson 
correlation. We used this definition to calculate an all-against-all similarity matrix for the 19 
inhibitors. Based on this similarity matrix, we performed average linkage clustering using the using 
the OC software (http://www.compbio.dundee.ac.uk/downloads/oc/). Finally, we visualized the 
resulting cluster tree as an unrooted tree using iTOL (http://itol.embl.de/).  
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Figure Legends 
Figure 1 | Quantitative profiling of the KDACI regulated acetylome. a, An overview of the 19 
KDACIs used for cell-based acetylome analysis and their reported specificities for human 
deacetylases based on cell-free assays. KDACs shown in dark grey background have been shown to 
be expressed in HeLa cells
65
. b, Schematic representation of the experimental design. SILAC labeled 
HeLa cells were treated for 16 h with KDAC inhibitors or vehicle control. Subsequently, proteins 
were extracted and proteolysed using Lys-C and trypsin. Acetylated peptides were enriched with 
anti-acetyllysine antibodies and fractionated by strong-cation exchange (SCX) chromatography. 
Peptides were analyzed by mass spectrometry and data were used for downstream bioinformatic 
analyses. c, The figure shows the number of acetylation sites quantified and the fraction of 
acetylation sites regulated by individual KDACIs. The left part of the figure shows total number of 
quantified acetylation sites for each inhibitor. The bar chart shows the fraction of upregulated sites 
(>2-fold increase, shown in red), and the fraction of down-regulated sites (>2-fold decrease, shown 
in blue). The numbers next to the bars indicate percent of up-or down-regulated sites, and the number 
of up- or down-downregulated sites for each KDACI is indicated within parenthesizes.  
Figure 2 | Specificity of KDACIs and subcellular distribution of KDACI-upregulated 
acetylated proteins. a, Site-based specificity analysis of KDACIs in HeLa cells. SILAC ratios of 
KDACI upregulated sites were used to calculate pair-wise Pearson correlation coefficients for all 
KDACIs and the inhibitors were grouped based on their correlation values using average linkage 
clustering approach (see supplemental fig. 14 for pair-wise correlations). Node-size reflects number 
of upregulated sites, and line thickness corresponds to the degree of correlation. b, Subcellular 
distribution of proteins with KDACI-upregulated acetylation sites. The bar plot shows the fraction of 
KDACI-upregulated acetylated proteins annotated with the indicated Gene Ontology cellular 
compartment (GOCC) terms. As a reference, the first bar indicates subcellular distribution of all 
acetylation sites identified in this study. The dendrogram at the top of the plot shows similarity of 
KDACIs for upregulated subcellular acetylomes. Sirtinol, JQ12 and PCI34051 were excluded from 
this analysis due to insufficient number of upregulated sites. c, Profile of KDACI-regulated histone 
acetylation sites. The heatmap shows quantified histone acetylation sites and their regulation by 
KDACIs. The dendrogram illustrates similarity of KDACIs for histone acetylation sites. Black 
matrix areas show sites not identified for an individual inhibitor. d, Overlap of acetylation sites 
upregulated in cells treated with broad-range KDACIs NAM, tenovin-6, tubacin, and PCI24781. The 
diagram displays the number of upregulated sites in response to each KDACI, as well as the number 
of sites found in two, three or all four of these inhibitors.  
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Figure 3 | Nicotinamide increases acetylation of nuclear proteins. a, Functional annotation of 
proteins containing NAM-upregulated acetylation sites in HeLa cells. Significantly enriched GO 
biological process (GOBP) terms associated with nuclear processes are indicated. Grey bars: all sites 
identified; black bars: upregulated sites b, The scatter plot shows the correlation between NAM-
regulated acetylation in MV4-11 and HeLa cells. Correlation was determined with Pearson 
correlation coefficient. c, The scatter plots show the correlation between acetylation sites quantified 
in biological replicate experiments for NAM treated WT MEFs, Sirt1
-/-
 MEFs, as well as between 
these two conditions. Correlation was determined with Pearson correlation coefficient. d, Functional 
annotation of proteins with NAM- or SIRT1-upregulated acetylation sites in MEF cells. Significantly 
enriched GO terms are indicated. Heatmap represents p-values for each term in comparison to whole 
mouse proteome. The numbers within boxes indicate hyperacetylated proteins covering the percent 
of proteins associated with the indicated GO terms.  
Figure 4 | Tubacin and bufexamac-mediated increase in protein acetylation is likely mediated 
by HDAC6. a, The scatter plot shows the correlation between acetylation sites quantified in tubacin- 
and bufexamac-treated HeLa cells. Correlation was determined with Pearson correlation coefficient. 
b, Verification of Hdac6 deletion in knockout MEFs. Expression of HDAC6 and acetylation of 
tubulin was analyzed by immunoblotting. c, The scatter plots show the correlation between 
acetylation sites identified in biological replicate experiments of tubacin- or bufexamac-treated MEF 
cells and Hdac6
-/-
 cells, as well as between each condition. Correlation was determined by Pearson 
correlation coefficient. d, Functional annotation of proteins with upregulated acetylation sites in 
bufexamac-, tubacin treated MEFs, or in Hdac6
-/-
 EFs. Significantly enriched GO terms are 
indicated. Heatmap represents p-values for each GO term in comparison to whole mouse proteome. 
The numbers within boxes indicate percent of hyperacetylated proteins associated with the indicated 
GO terms. 
Figure 5 | Bufexamac inhibits KDACs at lower concentrations and causes hypoxia-like 
responses at higher concentrations. a, Treatment of HeLa cells with 1 mM bufexamac results in 
the induction of HIF1-α, as determined by immunoblotting. The known hypoxia mimetics CPX and 
DFX were used as positive controls; vinculin served as loading control. b, Verification of 
bufexamac-specific upregulation of HIF1-α. HIF1-α protein expression was analyzed 4h after 
treatment of cells with the indicated compounds. c, Time-course analysis of HIF1-α induction by 
bufexamac. The induction of HIF1-α protein was analyzed by immunoblotting. The graph shows 
rapid stabilization of HIF1-α upon bufexamac treatment with half maximal intensity I1/2 of about 75 
min. Error bars represent SD of three independent experiments. d, HIF1-α is only stabilized at higher 
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concentrations of bufexamac and accumulates in the nucleus. Induction of endogenous HIF1-α and 
its nuclear accumulation was analyzed using immunofluorescence microscopy; white bar: 10 µm. e, 
Bufexamac increases transcriptional activity of HIF1-α. Luciferase activity was measured in HeLa 
cells transfected with HRE-Luciferase reporter upon treatment with CPX, DFX or bufexamac. Error 
bars represent SD of three independent experiments. f, Bufexamac treatment increases expression of 
HIF1-α target vascular endothelial growth factor A. Vegfa mRNA levels were assessed by real-time 
PCR and the data were normalized to Gapdh. Error bars represent SD of two independent 
experiments. g, Dose-response curves of bufexamac treated cells and the corresponding immunoblots 
are shown (HIF-1α and acetyl-tubulin were visualized simultaneously by using a mixture of anti-
HIF-1α and K40-acetyl-tubulin antibodies). Error-bars represent SD from 3 independent 
experiments. Lower panel shows immunofluorescence images of HeLa cells treated with 50 µM and 
250 µM bufexamac and immunostained for tubulin acetylation. white bar: 10 µm. h, Dose-response 
plot showing HIF1-α protein levels and a representative corresponding immunoblot. Cells were 
treated with 250 µM bufexamac and with the indicated concentrations of FeCl3. Data were 
normalized to the maximal HIF1-α expression; error bars represent SD from three independent 
experiments. i, Iron supplementation dose-dependently inhibits bufexamac-induced HIF1-α 
transcriptional activity. Cells were transfected with a HRE-Luciferase reporter plasmid and luciferase 
activity was measured after treatment with 250 µM bufexamac and different concentrations of 
FeCl3as indicated. Error bars represent SD of three independent experiments. CPX, ciclopirox 
olamine; DFX, deferoxamine; HRE, hypoxia response element; Gapdh, glycerol aldehyde 3 
phosphate dehydrogenase 
 
